Bisphosphonates in the Treatment of Osteoporosis
Bisphosphonates in the Treatment of Osteoporosis
复制标题
DOI：
10.1016/j.ecl.2012.04.007
复制
发表时间：
2012-09-01
影响因子：
4.5
通讯作者：
Watts, Nelson B.
中科院分区：
文献类型：
--
作者：
Diab, Dima L.;Watts, Nelson B.
双膦酸盐广泛用于治疗骨质疏松症，以降低骨折风险。由于它们在骨中的保留时间长和不常见的副作用，人们对治疗的最佳持续时间提出了质疑。潜在的副作用似乎是罕见的，可能没有因果关系。虽然没有强有力的科学来指导“药物假期”，但当治疗停止时，似乎有一些挥之不去的抗骨折益处，因此应该为大多数长期双膦酸盐治疗的患者提供一段时间的治疗。对于大多数骨质疏松症患者来说，治疗的好处大于风险。
Bisphosphonates are widely used in the treatment of osteoporosis to reduce fracture risk. Because of their long retention time in bone and uncommon side effects, questions have been raised about the optimal duration of therapy. Potential side effects appear to be rare and may not be causally related. Although there is no strong science to guide "drug holidays," there appears to be some lingering antifracture benefit when treatment is stopped, so some time off treatment should be offered to most patients on long-term bisphosphonate therapy. For most patients with osteoporosis, the benefits of treatment outweigh the risks.